Anwendung von Omalizumab-Biosimilars bei CRSwNP im deutschen Gesundheitssystem – ein Positionspapier von AeDA und DGHNO-KHC
L. Klimek, F. Bärhold, U. Förster-Ruhrmann, F. Klimek, C. Rott, A. G. Beule, A. Chaker, J. Hagemann, T. Huppertz, T. K. Hoffmann, S. Dazert, T. Deitmer, H. Olze, S. Strieth, H. Wrede, W. Schlenter, H. J. Welkoborsky, B. Wollenberg, T. Albrecht, C. Rudack, M.… · Pädiatrische Praxis · 2026 · Heft 04 · S. 210-223
Bibliografische Angaben
Zusammenfassung
Abstract Background Chronic rhinosinusitis with nasal polyps (CRSwNP) is a multifactorial inflammatory disease of the nasal and paranasal mucosa, most often caused by TH2 inflammation. IgE antibodies play an important role in this disease. The anti-IgE antibody omalizumab was approved in August 2020 for the treatment of patients aged 18 years and older with severe CRSwNP as add-on therapy to intranasal corticosteroids (INCS) when adequate disease control cannot be achieved with INCS alone. Omlyclo, a biosimilar of Xolair containing the active ingredient omalizumab (CT-P39), was approved in the EU in May 2024. In…
